Hepatocellular carcinoma in HIV positive patients

G. Nunnari, M. Berretta, M. R. Pinzone, M. Di Rosa, S. Berretta, G. Cunsolo, M. Malaguarnera, S. Cosentino, P. De Paoli, J. M. Schnell, B. Cacopardo

Research output: Contribution to journalArticlepeer-review


Highly active antiretroviral therapy (HAART) has dramatically changed the natural history of HIV-1-Infected patients leading to increased survival and a better quality of life. Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are common among HIV-1-Infected subjects and represent the most important risk factors for hepatocellular carcinoma (HCC). Whether HIV plays a direct role in hepatocellular carcinoma (HCC) pathogenesis remains to be established. HCC clinical course depends on stage of cancer disease, performance status and comorbidities. Therapeutic options include liver transplantation, local antiblastic chemotherapy and biological drugs. In the HIV setting few data are available about treatment options. The increased longevity of patients with HIV imposes new strategies for prevention and therapeutic management of patients. The aim of this article is to provide an up-To-Date review of HIV-Related HCC in the HAART era.

Original languageEnglish
Pages (from-to)1257-1270
Number of pages14
JournalEuropean Review for Medical and Pharmacological Sciences
Issue number9
Publication statusPublished - Sept 2012


  • Co-Infection
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • HIV
  • Liver transplant

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)


Dive into the research topics of 'Hepatocellular carcinoma in HIV positive patients'. Together they form a unique fingerprint.

Cite this